MedTrace Logo

Clarithromycin as Adjuvant to Periodontal Debridement

NCT02829983 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-11-21

Study results available
· View outcomes & findings →

Summary

To assess the periodontal clinical response and the possible adverse effects of the clarithromycin combined to periodontal mechanical therapy in the treatment of patients with generalized aggressive periodontitis.

Conditions

  • Aggressive Periodontitis

Interventions

DRUG

Clarithromycin

Use of 500mg of Clarithromycin twice a day for 3 days

DRUG

Placebo

Use of placebo tablets twice a day for 3 days.

OTHER

One-stage full-mouth ultrasonic debridement (FMUD)

One session of Periodontal debridement using ultrasonic device.

Sponsors & Collaborators

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

    collaborator OTHER_GOV

  • Universidade Estadual Paulista Júlio de Mesquita Filho

    lead OTHER

Principal Investigators

  • Mauro P Santamaria, DDS, PhD · UPECLIN HC FM Botucatu Unesp

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-08-31
Completion
2015-11-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02829983 on ClinicalTrials.gov